Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Cancer Intervention: Drug: Anti-EGFR monoclonal antibody Sponsors: Sinocelltech Ltd.; Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Cancer | Cancer & Oncology | Carcinoma | China Health | Head and Neck Cancer | HNSCC | Hospitals | Skin Cancer | Squamous Cell Carcinoma